Want to see IN:ORCHPHARMA full AI Analyst Report?
Top Page
Orchid Pharma Limited
(ORCHPHARMA)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹978.00
▼(-1.00% Downside)
Action:Reiterated
Date:07/09/26
The score is driven by mixed fundamentals: a stronger balance sheet and prior profitability improvements are offset by FY2026 margin/revenue deterioration and inconsistent cash generation with recurring negative free cash flow. Technicals are supportive (price above major moving averages with positive MACD), but valuation is a notable headwind given the very high P/E.
Positive Factors
Conservative Balance Sheet
Lower leverage and a larger equity base provide financial resilience and reduce dependence on external funding. This supports the company’s ability to sustain operations and invest through periods of weaker pharmaceutical demand or profitability.
Negative Factors
FY2026 Revenue Decline
The latest revenue contraction interrupts the prior growth trend and raises concerns about demand, product performance, or competitive pressure. A sustained decline would weaken operating leverage and make future profitability recovery more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Lower leverage and a larger equity base provide financial resilience and reduce dependence on external funding. This supports the company’s ability to sustain operations and invest through periods of weaker pharmaceutical demand or profitability.
Read all positive factors
Orchid Pharma Limited (ORCHPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹48.42B
Dividend Yield16.67%
Average Volume (3M)5.10K
Price to Earnings (P/E)560.2
Beta (1Y)1.31
Revenue Growth10.83%
EPS Growth-89.82%
CountryIN
Employees871
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.71
Shares Outstanding50,719,105
10 Day Avg. Volume4,671
30 Day Avg. Volume5,097
Financial Highlights & Ratios
PEG Ratio-1.50
Price to Book (P/B)1.90
Price to Sales (P/S)3.02
P/FCF Ratio-8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8
Revenue Forecast (FY)₹12.88B
Orchid Pharma Limited Business Overview & Revenue Model
Company Description
Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products....
Orchid Pharma Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
72
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.43B | 8.11B | 9.22B | 8.19B | 6.66B | 5.60B |
| Gross Profit | 2.43B | 1.59B | 3.55B | 1.36B | 706.89M | 2.32B |
| EBITDA | 502.20M | 411.28M | 1.45B | 1.42B | 1.43B | 621.38M |
| Net Income | 86.67M | 205.47M | 996.57M | 921.66M | 463.18M | -19.51M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 19.11B | 16.88B | 15.54B | 12.25B | 11.11B |
| Cash, Cash Equivalents and Short-Term Investments | 832.11M | 840.74M | 1.83B | 45.24M | 275.21M | 48.27M |
| Total Debt | 0.00 | 3.63B | 1.75B | 1.35B | 3.31B | 2.68B |
| Total Liabilities | -12.88B | 6.23B | 4.21B | 3.84B | 5.37B | 4.63B |
| Stockholders Equity | 12.88B | 12.88B | 12.67B | 11.69B | 6.89B | 6.47B |
Cash Flow | ||||||
| Free Cash Flow | -1.47B | -2.74B | -1.31B | 611.77M | -665.75M | 780.71M |
| Operating Cash Flow | 115.10M | 1.10B | 192.15M | 1.26B | 183.38M | 924.75M |
| Investing Cash Flow | -906.39M | -2.96B | -269.31M | -3.12B | -312.14M | 1.13B |
| Financing Cash Flow | 1.00B | 1.72B | 252.22M | 1.67B | 311.66M | -2.17B |
Orchid Pharma Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹71.07B | 52.53 | ― | 0.22% | 20.59% | 27.16% | |
64 Neutral | ₹58.72B | 34.79 | ― | 0.50% | 18.56% | 60.06% | |
61 Neutral | ₹48.42B | 560.23 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹38.79B | 12.68 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹44.67B | 60.93 | ― | 0.02% | 16.70% | 18.73% | |
50 Neutral | ₹30.59B | -1,137.68 | ― | 0.45% | 15.49% | -112.78% |
* General Sector Average
IN:ORCHPHARMA
Orchid Pharma Limited
946.50
237.35
33.47%
IN:BLISSGVS
Bliss Gvs Pharma Limited
696.45
542.93
353.67%
IN:GUFICBIO
Gufic Biosciences Limited
446.95
90.63
25.44%
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
213.05
102.57
92.84%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
696.05
16.30
2.40%
IN:UNICHEMLAB
Unichem Laboratories Limited
569.45
65.35
12.96%
Orchid Pharma Limited Corporate Events
Orchid Pharma Completes Dhanuka Laboratories Merger, Ups Authorised Capital
Jul 10, 2026
Orchid Pharma Limited has implemented a merger scheme under which Dhanuka Laboratories Limited has been amalgamated into the company, with the scheme effective from July 10, 2026 and Dhanuka dissolved without winding up. The appointed date of the ...
Orchid Pharma Finalizes Merger with Dhanuka, Boosts Authorised Capital and Sets Record Date
Jul 10, 2026
Orchid Pharma Limited has announced that the merger scheme with Dhanuka Laboratories Limited has become effective as of July 10, 2026, resulting in the dissolution of the amalgamating company without winding up. The appointed date of the scheme is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.